Siri Tennebø Flåm1, Ragnar Gunnarsson1, Torhild Garen1, Benedicte Alexandra Lie2, Øyvind Molberg3. 1. Department of Medical Genetics, University of Oslo and Oslo University Hospital Ullevål, Rheumatology Unit, Department of Immunology, Oslo University Hospital Rikshospitalet, Oslo and Institute of Clinical Medicine, University of Oslo, Oslo, Norway. 2. Department of Medical Genetics, University of Oslo and Oslo University Hospital Ullevål, Rheumatology Unit, Department of Immunology, Oslo University Hospital Rikshospitalet, Oslo and Institute of Clinical Medicine, University of Oslo, Oslo, Norway. Department of Medical Genetics, University of Oslo and Oslo University Hospital Ullevål, Rheumatology Unit, Department of Immunology, Oslo University Hospital Rikshospitalet, Oslo and Institute of Clinical Medicine, University of Oslo, Oslo, Norway. 3. Department of Medical Genetics, University of Oslo and Oslo University Hospital Ullevål, Rheumatology Unit, Department of Immunology, Oslo University Hospital Rikshospitalet, Oslo and Institute of Clinical Medicine, University of Oslo, Oslo, Norway. Department of Medical Genetics, University of Oslo and Oslo University Hospital Ullevål, Rheumatology Unit, Department of Immunology, Oslo University Hospital Rikshospitalet, Oslo and Institute of Clinical Medicine, University of Oslo, Oslo, Norway. oyvind.molberg@medisin.uio.no.
Abstract
OBJECTIVE: The Norwegian nationwide MCTD cohort was established to obtain unbiased data on key disease issues, and thereby reappraise the concept of MCTD. In the current study, the aims were to obtain detailed HLA profile data on the large Norwegian MCTD cohort and compare these with the HLA profiles of ethnically matched healthy controls and related CTD controls. METHODS: HLA profiles, determined by sequence-based typing of HLA-B* and DRB1*, were compared between four control groups of Norwegian ancestry, SLE (n = 96), SSc (n = 95), PM/DM (n = 84), healthy individuals (n = 282), the complete MCTD cohort (n = 155) and MCTD subsets defined by key clinical parameters. RESULTS: HLA-B*08 [odds ratio (OR) 2.05, P = 1.31 × 10(-4)) and DRB1*04:01 (OR 2.82, P = 3.64 × 10(-8)) were identified as risk alleles for MCTD, while DRB1*04:04, DRB1*13:01 and DRB1*13:02 were protective. Risk alleles for SLE and PM/DM were B*08 and DRB1*03:01. SSc risk was associated with DRB1*08:01. Analyses of MCTD subsets identified B*18 [OR 3.32 (95% CI 1.38, 8.01)] and DRB1*03:01 [OR 1.83 (95% CI 1.03, 3.25)] as independent risk factors for lung fibrosis. CONCLUSION: Novel HLA alleles associated with MCTD and disease subsets were identified and DRB1*04:01 was confirmed as a major risk allele. Altogether, the data reinforce the notion of MCTD as a disease entity distinct from SLE, SSc and PM/DM.
OBJECTIVE: The Norwegian nationwide MCTD cohort was established to obtain unbiased data on key disease issues, and thereby reappraise the concept of MCTD. In the current study, the aims were to obtain detailed HLA profile data on the large Norwegian MCTD cohort and compare these with the HLA profiles of ethnically matched healthy controls and related CTD controls. METHODS: HLA profiles, determined by sequence-based typing of HLA-B* and DRB1*, were compared between four control groups of Norwegian ancestry, SLE (n = 96), SSc (n = 95), PM/DM (n = 84), healthy individuals (n = 282), the complete MCTD cohort (n = 155) and MCTD subsets defined by key clinical parameters. RESULTS:HLA-B*08 [odds ratio (OR) 2.05, P = 1.31 × 10(-4)) and DRB1*04:01 (OR 2.82, P = 3.64 × 10(-8)) were identified as risk alleles for MCTD, while DRB1*04:04, DRB1*13:01 and DRB1*13:02 were protective. Risk alleles for SLE and PM/DM were B*08 and DRB1*03:01. SSc risk was associated with DRB1*08:01. Analyses of MCTD subsets identified B*18 [OR 3.32 (95% CI 1.38, 8.01)] and DRB1*03:01 [OR 1.83 (95% CI 1.03, 3.25)] as independent risk factors for lung fibrosis. CONCLUSION: Novel HLA alleles associated with MCTD and disease subsets were identified and DRB1*04:01 was confirmed as a major risk allele. Altogether, the data reinforce the notion of MCTD as a disease entity distinct from SLE, SSc and PM/DM.
Authors: Osman K Yilmaz; Stefanie Haeberle; Meifeng Zhang; Marvin J Fritzler; Alexander H Enk; Eva N Hadaschik Journal: Front Immunol Date: 2019-04-24 Impact factor: 7.561
Authors: Andreia Bettencourt; Cláudia Carvalho; Bárbara Leal; Sandra Brás; Dina Lopes; Ana Martins da Silva; Ernestina Santos; Tiago Torres; Isabel Almeida; Fátima Farinha; Paulo Barbosa; António Marinho; Manuela Selores; João Correia; Carlos Vasconcelos; Paulo P Costa; Berta Martins da Silva Journal: J Immunol Res Date: 2015-10-29 Impact factor: 4.818